1
|
Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba MG, Wen H, Sanders MA, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir OL, Yoon E, Rabe K, Soong TR, Reisenbichler ES, Rimm DL. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry. Mod Pathol 2023; 36:100032. [PMID: 36788069 PMCID: PMC10278086 DOI: 10.1016/j.modpat.2022.100032] [Citation(s) in RCA: 16] [Impact Index Per Article: 16.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 08/01/2022] [Accepted: 09/21/2022] [Indexed: 01/19/2023]
Abstract
The HercepTest was approved 20+ years ago as the companion diagnostic test for trastuzumab in human epidermal growth factor 2 (HER2) or ERBB2 gene-amplified/overexpressing breast cancers. Subsequent HER2 immunohistochemistry (IHC) assays followed, including the now most common Ventana 4B5 assay. Although this IHC assay has become the clinical standard, its reliability, reproducibility, and accuracy have largely been approved and accepted on the basis of concordance among small numbers of pathologists without validation in a real-world setting. In this study, we evaluated the concordance and interrater reliability of scoring HER2 IHC in 170 breast cancer biopsies by 18 breast cancer-specialized pathologists from 15 institutions. We used the Observers Needed to Evaluate Subjective Tests method to determine the plateau of concordance and the minimum number of pathologists needed to estimate interrater agreement values for large numbers of raters, as seen in the real-world setting. We report substantial discordance within the intermediate categories (<1% agreement for 1+ and 3.6% agreement for 2+) in the 4-category HER2 IHC scoring system. The discordance within the IHC 0 cases is also substantial with an overall percent agreement (OPA) of only 25% and poor interrater reliability metrics (0.49 Fleiss' kappa, 0.55 intraclass correlation coefficient). This discordance can be partially reduced by using a 3-category system (28.8% vs 46.5% OPA for 4-category and 3-category scoring systems, respectively). Observers Needed to Evaluate Subjective Tests plots suggest that the OPA for the task of determining a HER2 IHC score 0 from not 0 plateaus statistically around 59.4% at 10 raters. Conversely, at the task of scoring HER2 IHC as 3+ or not 3+ pathologists' concordance was much higher with an OPA that plateaus at 87.1% with 6 raters. This suggests that legacy HER2 IHC remains valuable for finding the patients in whom the ERBB2 gene is amplified but unacceptably discordant in assigning HER2-low or HER2-negative status for the emerging HER2-low therapies.
Collapse
Affiliation(s)
- Charles J Robbins
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut
| | - Aileen I Fernandez
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut
| | - Gang Han
- Department of Epidemiology & Biostatistics, Texas A and M University, College Station, Texas
| | - Serena Wong
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut
| | - Malini Harigopal
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut
| | - Mirna Podoll
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Kamaljeet Singh
- Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island
| | - Amy Ly
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - M Gabriela Kuba
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Hannah Wen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Mary Ann Sanders
- Department of Pathology, Norton Healthcare, Louisville, Kentucky
| | - Jane Brock
- Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts
| | - Shi Wei
- Department of Pathology, University of Kansas Medical Center, Kansas City, Kansas
| | - Oluwole Fadare
- Department of Pathology, University of California San Diego, San Diego, California
| | - Krisztina Hanley
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia
| | - Julie Jorns
- Department of Pathology, Medical College of Wisconsin, Milwaukee, Wisconsin
| | - Olivia L Snir
- Department of Pathology, Providence Health & Services, Portland, Oregon
| | - Esther Yoon
- Department of Pathology, MD Anderson, Cancer Center, Houston, Texas
| | - Kim Rabe
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota
| | - T Rinda Soong
- Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Emily S Reisenbichler
- Department of Pathology, SSM Health Saint Louis University Hospital, St. Louis, Missouri
| | - David L Rimm
- Department of Pathology, Yale School of Medicine, New Haven, Connecticut; Department of Medicine (Oncology), Yale School of Medicine, New Haven, Connecticut.
| |
Collapse
|
2
|
Han G, Schell MJ, Reisenbichler ES, Guo B, Rimm DL. Determination of the number of observers needed to evaluate a subjective test and its application in two PD-L1 studies. Stat Med 2021; 41:1361-1375. [PMID: 34897773 DOI: 10.1002/sim.9282] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 10/29/2021] [Accepted: 11/21/2021] [Indexed: 11/10/2022]
Abstract
In pathological studies, subjective assays, especially companion diagnostic tests, can dramatically affect treatment of cancer. Binary diagnostic test results (ie, positive vs negative) may vary between pathologists or observers who read the tumor slides. Some tests have clearly defined criteria resulting in highly concordant outcomes, even with minimal training. Other tests are more challenging. Observers may achieve poor concordance even with training. While there are many statistically rigorous methods for measuring concordance between observers, we are unaware of a method that can identify how many observers are needed to determine whether a test can reach an acceptable concordance, if at all. Here we introduce a statistical approach to the assessment of test performance when the test is read by multiple observers, as would occur in the real world. By plotting the number of observers against the estimated overall agreement proportion, we can obtain a curve that plateaus to the average observer concordance. Diagnostic tests that are well-defined and easily judged show high concordance and plateau with few interobserver comparisons. More challenging tests do not plateau until many interobserver comparisons are made, and typically reach a lower plateau or even 0. We further propose a statistical test of whether the overall agreement proportion will drop to 0 with a large number of pathologists. The proposed analytical framework can be used to evaluate the difficulty in the interpretation of pathological test criteria and platforms, and to determine how pathology-based subjective tests will perform in the real world. The method could also be used outside of pathology, where concordance of a diagnosis or decision point relies on the subjective application of multiple criteria. We apply this method in two recent PD-L1 studies to test whether the curve of overall agreement proportion will converge to 0 and determine the minimal sufficient number of observers required to estimate the concordance plateau of their reads.
Collapse
Affiliation(s)
- Gang Han
- Department of Epidemiology and Biostatistics, Texas A&M University School of Public Health, College Station, Texas, USA
| | - Michael J Schell
- Department of Biostatistics and Bioinformatics, Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
| | - Emily S Reisenbichler
- Department of Pathology, Saint Louis University School of Medicine, St. Louis, Missouri, USA
| | - Bohong Guo
- Department of Epidemiology and Biostatistics, Texas A&M University School of Public Health, College Station, Texas, USA
| | - David L Rimm
- Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA
| |
Collapse
|
3
|
Wang L, Asirvatham JR, Ma Y, Reisenbichler ES, Jorns JM. HER-2/neu-positive breast cancer neoadjuvant chemotherapy response after implementation of 2018 ASCO/CAP focused update. Breast J 2021; 27:631-637. [PMID: 34018281 DOI: 10.1111/tbj.14241] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/23/2021] [Accepted: 04/23/2021] [Indexed: 12/13/2022]
Abstract
Human Epidermal Growth Factor Receptor 2 (HER2), a routinely tested breast cancer marker, is associated with worse prognosis yet increased sensitivity to targeted neoadjuvant therapy (NAT) in breast cancer patients. The presence of HER2 in breast carcinoma can be detected with either immunohistochemistry (IHC) or in situ hybridization (ISH). In this study, we examine the relationship between clinicopathological features, HER2 detection method (IHC vs ISH), and prognostic outcomes in NAT-treated HER2-positive breast cancer patients. We included 99 HER2-positive patients from three academic institutions following 2018 HER2 testing updates and conducted a retrospective correlational study. Seventy-one (72%) were HER2-positive by IHC and 28 (28%) were positive following reflexive ISH. Multivariate analysis showed biomarker status to be significantly associated with pathologic complete response (pCR) (p = 0.003), Residual Cancer Burden (RCB) (p = 0.007), and tumor size downstaging (p = 0.002) and HER2 detection method of IHC to be significantly associated with pCR (p = 0.05), RCB (p = 0.004), and nodal downstaging (p= 0.03). In conclusion, HER2 detection method and biomarker subtype allow for further prognostic stratification of HER2-positive patients when 2018 American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline updates are applied.
Collapse
Affiliation(s)
- Lin Wang
- Medical College of Wisconsin, Milwaukee, WI, USA
| | | | - Yanlin Ma
- University of Virginia, Charlottesville, VA, USA
| | | | | |
Collapse
|
4
|
Friedrich AKU, Reisenbichler ES, Heller DR, LeBlanc JM, Park TS, Killelea BK, Lannin DR. Characteristics and Long-Term Risk of Breast Angiosarcoma. Ann Surg Oncol 2021; 28:5112-5118. [PMID: 33604827 DOI: 10.1245/s10434-021-09689-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 01/20/2021] [Indexed: 02/06/2023]
Abstract
BACKGROUND Angiosarcoma of the breast is rare and aggressive. It can occur as a de novo tumor or secondary to breast cancer treatment. The purpose of this study is to analyze differences between patients with primary and secondary angiosarcoma of the breast and investigate potential risk factors for its development. PATIENTS AND METHODS The Surveillance, Epidemiology, and End Results program of the National Cancer Institute database was queried to identify patients with angiosarcoma of the breast, trunk, shoulder, and upper arm. The population-based incidence was analyzed. Primary and secondary angiosarcoma cases were identified and compared. Breast cancer characteristics of secondary angiosarcoma patients were compared with all breast cancer patients in the database who did not develop angiosarcoma. RESULTS Overall, 904 patients were included, and 65.4% were secondary angiosarcomas. These patients had worse survival, were older, more likely to be White, more likely to have regionally advanced disease, and had angiosarcoma tumors of higher pathologic grade. Independent factors associated with development of secondary angiosarcoma among breast cancer patients included White race, older age, invasive tumor, lymph node removal, lumpectomy, radiation treatment, and left-sided tumor. Although the mean time to develop angiosarcoma after breast cancer diagnosis was 8.2 years, the risk continues to increase up to 30 years after breast cancer treatment. CONCLUSION Angiosarcoma is rare but increasing in incidence. Secondary angiosarcomas are more common and exhibit more aggressive behavior. Several factors for angiosarcoma after breast cancer treatment could be identified, which may help us counsel and identify patients at risk.
Collapse
Affiliation(s)
| | - Emily S Reisenbichler
- Departments of Pathology and Yale Comprehensive Cancer Center, Yale University School of Medicine, New Haven, CT, 06520, USA
| | - Danielle R Heller
- Department of Surgery, Yale University School of Medicine, New Haven, CT, 06520, USA
| | - Justin M LeBlanc
- Department of Surgery, Yale University School of Medicine, New Haven, CT, 06520, USA
| | - Tristen S Park
- Department of Surgery, Yale University School of Medicine, New Haven, CT, 06520, USA
| | - Brigid K Killelea
- St. Vincent's Medical Center, Hartford HealthCare, Bridgeport, CT , USA
| | - Donald R Lannin
- Department of Surgery, Yale University School of Medicine, New Haven, CT, 06520, USA.
| |
Collapse
|
5
|
Reisenbichler ES, Han G, Bellizzi A, Bossuyt V, Brock J, Cole K, Fadare O, Hameed O, Hanley K, Harrison BT, Kuba MG, Ly A, Miller D, Podoll M, Roden AC, Singh K, Sanders MA, Wei S, Wen H, Pelekanou V, Yaghoobi V, Ahmed F, Pusztai L, Rimm DL. Prospective multi-institutional evaluation of pathologist assessment of PD-L1 assays for patient selection in triple negative breast cancer. Mod Pathol 2020; 33:1746-1752. [PMID: 32300181 PMCID: PMC8366569 DOI: 10.1038/s41379-020-0544-x] [Citation(s) in RCA: 75] [Impact Index Per Article: 18.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2020] [Revised: 03/25/2020] [Accepted: 03/25/2020] [Indexed: 12/21/2022]
Abstract
The US Food and Drug Administration (FDA) approved the PD-L1 immunohistochemical assay, SP142, as a companion test to determine eligibility for atezolizumab therapy in patients with advanced triple negative breast cancer (TNBC) but data in lung cancer studies suggest the assay suffers from poor reproducibility. We sought to evaluate reproducibility and concordance in PD-L1 scoring across multiple pathologists. Full TNBC sections were stained with SP142 and SP263 assays and interpreted for percentage (%) immune cell (IC) staining by 19 pathologists from 14 academic institutions. Proportion of PD-L1 positive cases (defined as ≥1% IC) was determined for each assay as well as concordance across observers. We utilized a new method we call Observers Needed to Evaluate Subjective Tests (ONEST) to determine the minimum number of evaluators needed to estimate concordance between large numbers of readers, as occurs in the real-world setting. PD-L1 was interpreted as positive with the SP142 assay in an average 58% of cases compared with 78% with SP263 (p < 0.0001). IC positive continuous scores ranged from 1 to 95% (mean = 20%) and 1 to 90% (mean = 10%) for SP263 and SP142, respectively. With SP142, 26 cases (38%) showed complete two category (<1% vs. ≥1%) concordance; with SP263, 38 cases (50%) showed complete agreement. The intraclass correlation coefficient (ICC) for two category scoring of SP263 and SP142 was 0.513 and 0.560. ONEST plots showed decreasing overall percent agreement (OPA) as observer number increased, reaching a low plateau of 0.46 at ten observers for SP263 and 0.41 at eight observers for SP142. IC scoring with both assays showed poor reproducibility across multiple pathologists with ONEST analysis suggesting more than half of pathologists will disagree about IC scores. This could lead to many patients either receiving atezolizumab when they are unlikely to benefit, or not receiving atezolizumab when they may benefit.
Collapse
Affiliation(s)
| | - Gang Han
- Texas A&M University, College Station, TX, USA
| | | | | | - Jane Brock
- Brigham and Women's Hospital, Boston, MA, USA
| | | | | | - Omar Hameed
- Forward Pathology Solutions, Kansas City, MO, USA.,Vanderbilt University Medical Center, Nashville, TN, USA
| | | | | | | | - Amy Ly
- Massachusetts General Hospital, Boston, MA, USA
| | - Dylan Miller
- Intermountain Healthcare, Salt Lake City, UT, USA.,University of Utah, Salt Lake City, UT, USA
| | - Mirna Podoll
- Vanderbilt University Medical Center, Nashville, TN, USA
| | | | | | | | - Shi Wei
- University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - Vasiliki Pelekanou
- Yale School of Medicine, New Haven, CT, USA.,Sanofi Oncology US, Cambridge, MA, USA
| | | | | | | | | |
Collapse
|
6
|
Caruana D, Wei W, Martinez-Morilla S, Rimm DL, Reisenbichler ES. Association between low estrogen receptor positive breast cancer and staining performance. NPJ Breast Cancer 2020; 6:5. [PMID: 32047851 PMCID: PMC7002746 DOI: 10.1038/s41523-020-0146-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Accepted: 01/09/2020] [Indexed: 12/17/2022] Open
Abstract
Estrogen receptor (ER) expression in breast carcinomas, determined by immunohistochemistry, indicates statistically significant benefit to endocrine therapy in patients with tumors expressing ER in ≥1% of tumor cells. Rare cases with low ER expression (1-10%) lead to the dilemma of treating these tumors as ER positive or negative. We hypothesize that low ER positive result from poor staining performance and that we may detect this artefact by assessing the average dynamic range of normal ducts adjacent to low ER positive tumors. Using quantitative tools, we compare the dynamic range of normal background ER expression in patients with low (1-10%) ER tumors to dynamic range of ER expression in normal epithelium from control patient populations, to determine if low ER cases are accompanied by decreased dynamic range. Low ER cases were infrequent (1% of invasive breast carcinomas). Twenty-one cases with low ER staining and two control cohorts, including a tissue microarray (TMA) of 10 benign breast sections and a group of 34 control breast carcinomas (reported as ER negative or >10% ER positive) with normal background epithelium, were digitally scanned. QuPath was utilized to quantify ER staining for each cell as the mean optical density of nuclear DAB staining. The dynamic range of ER expression in normal epithelium surrounding low ER tumors was significantly lower (range 2-240, median 16.5) than that of the benign epithelium in the control tumors (range 3-475, median 30.8; p < 0.001) and benign TMA sections (range 38-212, median 114; p < 0.001) suggesting inconsistent stainer performance.
Collapse
Affiliation(s)
- Dennis Caruana
- Department of Pathology, Yale University School of Medicine, New Haven, CT USA
| | - Wei Wei
- Yale University School of Public Health, New Haven, CT USA
| | | | - David L. Rimm
- Department of Pathology, Yale University School of Medicine, New Haven, CT USA
- Department of Oncology, Yale University School of Medicine, New Haven, CT USA
| | | |
Collapse
|
7
|
Rabe K, Snir OL, Bossuyt V, Harigopal M, Celli R, Reisenbichler ES. Interobserver variability in breast carcinoma grading results in prognostic stage differences. Hum Pathol 2019; 94:51-57. [PMID: 31655171 DOI: 10.1016/j.humpath.2019.09.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/19/2019] [Accepted: 09/06/2019] [Indexed: 10/25/2022]
Abstract
The AJCC Cancer Staging Manual 8th edition included tumor grade in the pathologic prognostic stage for breast carcinomas. Due to the known subjectivity of tumor grading, we aimed to assess the degree of interobserver agreement for invasive carcinoma grade among pathologists and determine its effect on pathologic prognostic stage. One hundred consecutive cases of invasive stage II carcinomas were independently graded twice, with an 4-week intervening wash-out period, by 6 breast pathologists utilizing established Nottingham grading criteria. Inter- and intra-observer variability was determined for overall grade and for each of the 3 scoring components. Interobserver variability was good to very good (κ range = 0.582-0.850) with even better intra-observer variability (mean κ = 0.766). Tubule score was the most reproducible element (κ = 0.588). Complete concordance was reached in 54 cases and 58 cases in rounds 1 and 2 respectively. In round 1 this resulted in different pathologic prognostic stage in only 25 of discordant cases, 18 of which were stage IA versus IB. In conclusion, grading agreement between pathologists was good to very good and discordant grades resulted in small changes to pathologic prognostic stage.
Collapse
Affiliation(s)
- Kimmie Rabe
- Department of Pathology, Yale University School of Medicine New Haven, New Haven, CT
| | - Olivia L Snir
- Department of Pathology, Oregon Health and Science University School of Medicine, Portland, OR
| | - Veerle Bossuyt
- Department of Pathology, Massachusetts General Hospital, Boston, MA
| | - Malini Harigopal
- Department of Pathology, Yale University School of Medicine New Haven, New Haven, CT
| | - Romulo Celli
- Department of Pathology, Yale University School of Medicine New Haven, New Haven, CT
| | - Emily S Reisenbichler
- Department of Pathology, Yale University School of Medicine New Haven, New Haven, CT.
| |
Collapse
|
8
|
Compton ML, Hogan M, Reisenbichler ES. Differences in immunohistochemistry utilization by general and breast subspecialty pathologists at a large academic institution. Ann Diagn Pathol 2019; 42:92-95. [PMID: 31445409 DOI: 10.1016/j.anndiagpath.2019.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2019] [Revised: 08/15/2019] [Accepted: 08/16/2019] [Indexed: 11/24/2022]
Abstract
OBJECTIVES Immunohistochemistry (IHC) can be a useful adjunct in diagnostic breast pathology, but best practices have not been clearly established. We sought to compare the patterns of p63 utilization between general pathologists (GP) and subspecialized breast pathologists (BP), analyze diagnostic discrepancy rates, and identify types of lesions requiring immunohistochemistry. METHODS The pathology database was searched over 6-year period to identify breast needle core biopsy cases utilizing p63 and subsequent excision results. RESULTS P63 was ordered more frequently by BP (2.3% of cores) compared to GP (1.1% of cores, p = 0.0005). The most frequent utilization of p63 by GP for benign lesions (44.0%) followed by invasive carcinomas (36.0%) while BP most frequently ordered p63 on invasive carcinomas (49.5%) and DCIS (26.6%). CONCLUSIONS While IHC use may be thought to be most helpful to those with less experience or knowledge in breast pathology, these results suggest that utilization is increased with subspecialty training.
Collapse
Affiliation(s)
- Margaret L Compton
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, MCN CC3322, Nashville, TN 37232-2561, United States of America.
| | - Melissa Hogan
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, United States of America
| | - Emily S Reisenbichler
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, United States of America; Department of Pathology, Yale-New Haven Health System, United States of America
| |
Collapse
|
9
|
Straub MM, Wheeler FC, Deraney SM, Reisenbichler ES. Lack of MDM2 interpretation guidelines contribute to diagnostic difficulty in a case of undifferentiated sarcoma. Human Pathology: Case Reports 2018. [DOI: 10.1016/j.ehpc.2018.03.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
10
|
Compton ML, Sweeting RS, Reisenbichler ES. Intraoperative sentinel lymph node evaluation: Optimizing surgical pathology practices in an era of changing clinical management. Ann Diagn Pathol 2018; 33:45-50. [DOI: 10.1016/j.anndiagpath.2017.12.003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2017] [Accepted: 12/11/2017] [Indexed: 12/25/2022]
|
11
|
Podoll MB, Reisenbichler ES, Roland L, Bruner A, Mizuguchi S, Sanders MAG. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery. Arch Pathol Lab Med 2018; 142:1120-1126. [PMID: 29582675 DOI: 10.5858/arpa.2017-0268-oa] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT - Ductal carcinoma in situ (DCIS) represents 20% of screen-detected breast cancers. The likelihood that certain types of DCIS are slow growing and may never progress to invasion suggests that our current standards of treating DCIS could result in overtreatment. The LORIS (LOw RISk DCIS) and LORD (LOw Risk DCIS) trials address these concerns by randomizing patients with low-risk DCIS to either active surveillance or conventional treatment. OBJECTIVE - To determine the upgrade rate of DCIS diagnosed on core needle biopsy to invasive carcinoma at surgery and to evaluate the safety of managing low-risk DCIS with surveillance alone, by characterizing the pathologic and clinical features of upgraded cases and applying criteria of the LORD and LORIS trials to these cases. DESIGN - A 10-year retrospective analysis of DCIS on core needle biopsy with subsequent surgery. RESULTS - We identified 1271 cases of DCIS on core needle biopsy: 200 (16%) low grade, 649 (51%) intermediate grade, and 422 (33%) high grade. Of the 1271 cases, we found an 8% upgrade rate to invasive carcinoma (n = 105). Nineteen of the 105 upgraded cases (18%) had positive lymph nodes. Low-grade DCIS was least likely to upgrade to invasion, comprising 10% (10 of 105) of upgraded cases. Three of the 105 upgraded cases (3%) met criteria for the LORD trial, and all were low-grade DCIS on core needle biopsy with favorable biology on follow-up. CONCLUSIONS - There is a clear risk of upgrade to invasion on follow-up excision; however, applying strict criteria of the LORD trial effectively decreases the likelihood of a missed invasive component or missed aggressive pathologic features.
Collapse
Affiliation(s)
| | | | | | | | | | - Mary Ann G Sanders
- From the Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, Tennessee (Drs Podoll and Reisenbichler); and the Departments of Radiology (Drs Roland, Bruner, and Mizuguchi) and Pathology and Laboratory Medicine (Dr Sanders), University of Louisville Hospital, Louisville, Kentucky
| |
Collapse
|
12
|
Sharma C, Wang HX, Li Q, Knoblich K, Reisenbichler ES, Richardson AL, Hemler ME. Protein Acyltransferase DHHC3 Regulates Breast Tumor Growth, Oxidative Stress, and Senescence. Cancer Res 2017; 77:6880-6890. [PMID: 29055014 DOI: 10.1158/0008-5472.can-17-1536] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2017] [Revised: 08/29/2017] [Accepted: 10/17/2017] [Indexed: 01/03/2023]
Abstract
DHHC-type protein acyltransferases may regulate the localization, stability, and/or activity of their substrates. In this study, we show that the protein palmitoyltransferase DHHC3 is upregulated in malignant and metastatic human breast cancer. Elevated expression of DHHC3 correlated with diminished patient survival in breast cancer and six other human cancer types. ZDHHC3 ablation in human MDA-MB-231 mammary tumor cell xenografts reduced the sizes of both the primary tumor and metastatic lung colonies. Gene array data and fluorescence dye assays documented increased oxidative stress and senescence in ZDHHC3-ablated cells. ZDHHC3-ablated tumors also showed enhanced recruitment of innate immune cells (antitumor macrophages, natural killer cells) associated with clearance of senescent tumors. These antitumor effects were reversed upon reconstitution with wild-type, but not enzyme-active site-deficient DHHC3. Concomitant ablation of the upregulated oxidative stress protein TXNIP substantially negated the effects of ZDHHC3 depletion on oxidative stress and senescence. Diminished DHHC3-dependent palmitoylation of ERGIC3 protein likely played a key role in TXNIP upregulation. In conclusion, DHHC3-mediated protein palmitoylation supports breast tumor growth by modulating cellular oxidative stress and senescence. Cancer Res; 77(24); 6880-90. ©2017 AACR.
Collapse
Affiliation(s)
- Chandan Sharma
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Hong-Xing Wang
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Qinglin Li
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Konstantin Knoblich
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Emily S Reisenbichler
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Andrea L Richardson
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts
| | - Martin E Hemler
- Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute and Department of Pathology, Harvard Medical School, Boston, Massachusetts.
| |
Collapse
|
13
|
Reisenbichler ES, Hameed O. Reporting the greatest linear extent of ductal carcinoma in situ on needle core biopsy. Hum Pathol 2016; 50:140-5. [DOI: 10.1016/j.humpath.2015.12.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/01/2015] [Revised: 12/02/2015] [Accepted: 12/10/2015] [Indexed: 11/28/2022]
|
14
|
Reisenbichler ES, Dupont W, Dale P, Hameed O. Abstract P6-08-13: Is there prognostic significance of tumor cellularity in primary non-treated breast carcinoma? Cancer Res 2015. [DOI: 10.1158/1538-7445.sabcs14-p6-08-13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Many factors such as tumor size, grade, lymph node and receptor status, either independently or in combination, as with the Nottingham Prognosic Index (NPI), are known to predict outcomes in non-treated breast cancer. With the growing use of neoadjuvant therapies, additional prognostic indicators have been identified for evaluating treated carcinomas. Many post-treatment methods of analysis rely on tumor cellularity (TC) either alone, as in the Miller-Payne system, or in combination with other tumor features, as in the Residual Cancer Burden (RCB) to predict distant relapse-free survival (RFS). It is not clear however, whether TC can predict outcomes in non-treated breast carcinoma. The goal of this study was to evaluate the prognostic value of TC in this particular setting.
Design: TC (%), excluding foci of necrosis and in-situ carcinoma, was determined from histologic review of a representative tumor section in the primary excision of 366 invasive breast carcinomas and categorized into quartiles. Prior detailed histology review included tumor size (TS), histological type and grade, receptor and lymph node status, RFS and overall survival (OS). Nottingham Prognostic Index (NPI) was calculated for each case (0.2 x tumor size (cm) + lymph node stage (1, node negative; 2, 1-3 positive nodes; 3, ≥ 4 positive nodes) + histologic grade).
Results: Mean patient age was 58 yr (range, 21-91) and median follow-up was 87 mo (range, 0.7-165). Invasive ductal carcinoma of no special type constituted 80% of cases, invasive lobular carcinoma 10%, and other special types of carcinoma, 10%. Nottingham grades I, II and III, represented 25%, 41% and 32% of the cases, respectively (unknown in 4). Mean NPI was 3.93 (range, 2.06–6.8). Estrogen receptor was positive in 66% and negative in 25% of cases (unknown in 9%). TC ranged from 2-99% (mean 47.6%). As expected, NPI was predictive of OS (p=0.000; hazard ratio 1.726; 95% confidence interval 1.45-2.05) and RFS (p=0.000; hazard ratio 2.011; 95% confidence interval 1.62-2.50). TC, unadjusted for other covariates was not predictive of OS or RFS (Table 1). The same analysis of ER positive and negative subgroups continued to show no relation of TC to OS or RFS (Table 2). When adjusted for NPI, TC still showed no significant relation to OS or RFS (data not shown).
Table 1 TC QuartileHazard Ratio*P Value95% Confidence IntervalOS, unadjusted20.7790.3150.48-1.27 31.0730.7690.67-1.73 40.9780.9340.58-1.65RFS, unadjusted20.9680.9130.54-1.75 30.9210.7980.49-1.73 41.0380.9130.53-2.01
Table 2Estrogen Positive Carcinomas TC QuartileHazard Ratio*P Value95% Confidence IntervalOS, unadjusted20.8240.5810.42-1.64 31.2240.5350.65-2.21 41.5640.1640.83-2.94RFS, unadjusted20.6540.2990.29-1.46 30.8130.6020.37-1.77 40.8910.7780.40-1.98Estrogen Negative Carcinomas TC QuartileHazard Ratio*P Value95% Confidence IntervalOS, unadjusted21.0900.8390.78-2.49 30.7080.4140.31-1.62 40.4880.1380.19-1.26RFS, unadjusted23.0480.0311.10-8.41 31.2120.7390.39-3.76 40.8200.7590.23-2.91*Relative to 1st quartile
Conclusion: Despite its utility in the neoadjuvant setting, TC does not offer the same prognostic value in the setting of untreated tumors and is not predictive of OS or RFS in primary non-treated carcinomas.
Citation Format: Emily S Reisenbichler, William Dupont, Plummer Dale, Omar Hameed. Is there prognostic significance of tumor cellularity in primary non-treated breast carcinoma? [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-08-13.
Collapse
|
15
|
Reisenbichler ES, Ross JR, Hameed O. The clinical use of a P63/cytokeratin7/18/cytokeratin5/14 antibody cocktail in diagnostic breast pathology. Ann Diagn Pathol 2014; 18:313-8. [PMID: 25224390 DOI: 10.1016/j.anndiagpath.2014.08.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Revised: 08/18/2014] [Accepted: 08/21/2014] [Indexed: 10/24/2022]
Abstract
An antibody cocktail directed against p63, cytokeratin (CK)5/14, and CK7/18 is reported to be useful in distinguishing noninvasive from invasive breast lesions and for the characterization of intraductal epithelial proliferations. However, limited studies evaluate its use in clinical practice. A retrospective review of breast material at a university medical center identified cases that were immunostained with the above antibody cocktail. Additional p63 immunostaining alone was performed to further determine the utility of the antibody cocktail in the evaluation of invasion. Of 50 breast cases identified, the antibody cocktail was used to confirm or exclude invasion in 44 (88%). Twenty-two (50%) of these had easily identifiable p63/CK5/14-positive myoepithelial cells, whereas the remainder lacked such staining, confirming the diagnosis of invasive carcinoma. In 27 cases with available diagnostic material for additional p63 immunostaining, the cocktail better highlighted myoepithelial cells by staining nuclei and cytoplasm. Easier identification of invasion was also facilitated by CK7/18 expression in invasive foci, especially those composed of single cells. Ten cases were immunostained to help determine the nature of an intraductal proliferation. The cocktail demonstrated a mosaic staining pattern of both CK7/18- and CK5/14-positive epithelial cells in 3 (30%) cases consistent with usual hyperplasia; homogenous CK7/18 expression in the remaining cases supported the diagnosis of atypical ductal hyperplasia or carcinoma in situ. In summary, the p63/CK7/18/CK5/14 cocktail stain appears to be a useful tool in diagnostic breast pathology, in the evaluation of possible invasion, particularly in the setting of minute foci of invasion as well as in epithelial proliferations.
Collapse
Affiliation(s)
- Emily S Reisenbichler
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Ave South CC-3322 Medical Center North, Nashville, TN 37232-2561, USA.
| | - John R Ross
- Department of Pathology, University of Alabama at Birmingham, P210 West Pavilion 619 South 19th St Birmingham, AL 35233-7331, USA
| | - Omar Hameed
- Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Ave South CC-3322 Medical Center North, Nashville, TN 37232-2561, USA; Department of Surgery, Vanderbilt University Medical Center, 1161 21st Ave South CC-3322 Medical Center North, Nashville, TN 37232-2561, USA; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, 1161 21st Ave South CC-3322 Medical Center North, Nashville, TN 37232-2561, USA
| |
Collapse
|
16
|
Abstract
Magnetic resonance imaging (MRI) of the breast is used for select groups of patients. MRI-guided breast core needle biopsies performed over a 3-year period were retrospectively reviewed to determine the incidence and types of cancers found and to correlate the cancers with the MRI findings and the indication for the study. Patients were stratified based on indication for MRI examination including, evaluation of disease extent in patients with current ipsilateral carcinoma, surveillance for recurrence of prior ipsilateral carcinoma, as a problem-solving method and for screening high-risk patients. The high-risk screening group included those with family history (with or without germline mutations), prior chest wall radiation, and contralateral breast carcinoma (current or prior). Four-hundred and forty-five biopsies were performed on 386 patients. The majority of biopsies (79%) were benign. Biopsies demonstrating ductal carcinoma in situ (DCIS) and invasive carcinoma were more likely to present as nonmass-like and mass-forming enhancements respectively, but with only 52% specificity. The highest rate of malignancy (44%) was seen in the least frequently biopsied patient group (n = 25), those with prior ipsilateral carcinoma. Conversely, the most frequently biopsied group (n = 283), the high-risk screening group, demonstrated the lowest malignancy rate (16%). Within this group, most malignant cases were invasive carcinomas (n = 27), 67% of which were small (≤1 cm), well or moderately differentiated with a good prognostic receptor profile (estrogen receptor positive, human epidermal growth factor receptor 2 negative), and lacked nodal macrometastases. The remaining malignant cases in the high-risk screening group were DCIS with or without microinvasion (n = 18), 78% of which demonstrated high nuclear grade. Overall, enhancement pattern did not correlate with the likelihood of or type of malignancy. The most common types of carcinomas identified by screening were small estrogen receptor positive invasive tumors and high grade DCIS.
Collapse
Affiliation(s)
- Elizabeth Manion
- Department of Pathology, Saint Luke's Hospital System, Kansas City, Missouri
| | | | | | | |
Collapse
|
17
|
Reisenbichler ES, Adams AL, Hameed O. The predictive ability of a CK5/p63/CK8/18 antibody cocktail in stratifying breast papillary lesions on needle biopsy: an algorithmic approach works best. Am J Clin Pathol 2013; 140:767-79. [PMID: 24225742 DOI: 10.1309/ajcpxv64gxlzciga] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Abstract
OBJECTIVES Immunohistochemical markers have been shown to assist in the stratification of breast papillary lesions. We evaluated the ability of different cytokeratin (CK) and p63 expression profiles on needle biopsy specimens to predict excision diagnoses. METHODS A CK5/p63/CK8/18 antibody cocktail was applied to 58 needle biopsy specimens (32 papillomas, 7 atypical papillomas, 19 papillary carcinomas on excision). RESULTS p63 expression was greater in papillomas than in atypical papillomas (P = .044) and papillary carcinomas (P< .0001). Papillary carcinomas and atypical papillomas showed greater CK8/18 expression (and conversely less CK5 expression) than did papillomas (P < .0001). Negative or focal p63 expression was 96% sensitive for diagnosing any atypical lesion (atypical papilloma or papillary carcinoma) on excision, whereas CK8/18 predominant expression (≥80% cells) was 100% sensitive. In contrast, the sensitivity of the original diagnosis was only 81%. The greatest accuracy for the diagnosis of atypical papillary lesions (95%) was achieved when both p63 and cytokeratins were used in combination in an algorithmic fashion. This method also correctly identified all cases that had papillary carcinoma (100% sensitivity) on excision. CONCLUSIONS Although a single stain or combination cannot independently stratify papillary lesions, a CK5/p63/CK8/18 antibody cocktail is a useful adjunct to morphology for evaluating breast papillary lesions in needle biopsy specimens.
Collapse
Affiliation(s)
| | - Amy L. Adams
- Department of Pathology, University of Alabama at Birmingham, Atlanta, GA
- Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA
| | - Omar Hameed
- Department of Pathology, University of Alabama at Birmingham, Atlanta, GA
- Department of Pathology, Microbiology and Immunology, Vanderbilt University, Nashville, TN
- Department of Surgery, Vanderbilt University, Nashville, TN
- The Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN
| |
Collapse
|
18
|
Reisenbichler ES, Lester SC, Richardson AL, Dillon DA, Ly A, Brock JE. Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am J Clin Pathol 2013; 140:487-94. [PMID: 24045544 DOI: 10.1309/ajcp1rf9fuizrdpi] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022] Open
Abstract
OBJECTIVES Endocrine therapy reduces recurrence risk by 30% to 50% in estrogen receptor (ER)-positive breast cancer. The ER-positive threshold recommended by the American Society of Clinical Oncology/College of American Pathologists is 1% based on studies using the ER-6F11 antibody. ER-SP1 antibody has a higher sensitivity and is more widely used. METHODS We report interobserver concordance manually measuring ER in 264 breast cancers using ER-SP1 and 1D5 and 2 scoring methods (H-score and Allred score). RESULTS With both antibodies, 3% to 4% of cases have a low level of ER expression (1%-10%), more than previously reported (<1%). We find a high level of paired observer concordance with both antibodies and scoring methods (κ = 0.892-0.943) with no significant difference with method of scoring. Despite excellent concordance, positive/negative discordance was almost 5% among 3 observers using either antibody, an underappreciated clinically significant rate. CONCLUSIONS Discordance overwhelmingly reflected differing opinions recording the proportion of tumor cells positive with low levels of expression (<10% staining; 12/13 cases).
Collapse
Affiliation(s)
| | - Susan C. Lester
- Department of Pathology, Brigham and Women’s Hospital, Boston, MA
| | | | | | - Amy Ly
- Massachusetts General Hospital, Boston
| | - Jane E. Brock
- Department of Pathology, Brigham and Women’s Hospital, Boston, MA
| |
Collapse
|
19
|
Reisenbichler ES, Horton D, Rasco M, Andea A, Hameed O. Evaluation of dual immunohistochemistry and chromogenic in situ hybridization for HER2 on a single section. Am J Clin Pathol 2012; 137:102-10. [PMID: 22180483 DOI: 10.1309/ajcplnhinn9o6ysf] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
Abstract
The evaluation of HER2 status in invasive breast carcinoma can be performed by multiple methods. We assessed the feasibility of performing 2 of these, chromogenic in situ hybridization (CISH) and immunohistochemical staining, on single tissue sections of breast carcinoma. During assay development, sequential performance of immunohistochemical staining after CISH resulted in weaker HER2 expression than that obtained when immunohistochemical staining was performed alone; this was ameliorated by increased antibody incubation time. Performance of both techniques in a combined/hybrid protocol resulted in HER2 protein expression and gene signals identical to those produced by the individual techniques performed alone. Prospective validation of these dual staining protocols in 31 cases of breast carcinoma resulted in 100% concordance with results of CISH when performed alone, but was still associated with a reduced immunohistochemical signal in some cases. Although further testing is needed, we conclude that performance of both immunohistochemical staining and CISH on a single section is possible and could allow for direct "cell-by-cell" comparison of HER2 signals and potentially offer a more economical and real-time method for ongoing validation of HER2 testing.
Collapse
|
20
|
Reisenbichler ES, Hameed O. Non-Trophoblastic Tumors as Other Causes of Elevated Human Chorionic Gonadotrophin. Lab Med 2010. [DOI: 10.1309/lmhzd8oulkxf77pk] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
21
|
Reisenbichler ES, Krontiras H, Hameed O. Βeta-Human Chorionic Gonadotropin Production Associated with Phyllodes Tumor of the Breast: An Unusual Paraneoplastic Phenomenon. Breast J 2009; 15:527-30. [DOI: 10.1111/j.1524-4741.2009.00772.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
22
|
Brown EL, Kim JH, Reisenbichler ES, Höök M. Multicomponent Lyme vaccine: three is not a crowd. Vaccine 2005; 23:3687-96. [PMID: 15882529 DOI: 10.1016/j.vaccine.2005.02.006] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2004] [Revised: 01/10/2005] [Accepted: 02/04/2005] [Indexed: 11/21/2022]
Abstract
Lyme disease is caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne disease in the United States. Disseminated spirochetes can persist in various tissues and can result in a variety of different disease manifestations. Vaccination trials testing various lipoprotein candidates have yielded mixed results despite the generation of robust antibody titers. Data presented in this report demonstrate that a combination vaccine composed of DbpA, BBK32 and OspC is more effective than single or double component formulations and that the ratio of each component dramatically impacts vaccine efficacy when tested in protection experiments against Borrelia following needle inoculation.
Collapse
MESH Headings
- Adhesins, Bacterial/administration & dosage
- Adhesins, Bacterial/immunology
- Animals
- Antibodies, Bacterial/blood
- Antigens, Bacterial/administration & dosage
- Antigens, Bacterial/immunology
- Bacterial Outer Membrane Proteins/administration & dosage
- Bacterial Outer Membrane Proteins/immunology
- Bacterial Proteins/administration & dosage
- Bacterial Proteins/immunology
- Borrelia burgdorferi/immunology
- Disease Models, Animal
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Immunoglobulin G/blood
- Lyme Disease/prevention & control
- Lyme Disease Vaccines/administration & dosage
- Lyme Disease Vaccines/immunology
- Mice
- Mice, Inbred BALB C
- Vaccines, Subunit/administration & dosage
- Vaccines, Subunit/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
Collapse
Affiliation(s)
- Eric L Brown
- The Center for Extracellular Matrix Biology, Texas A&M University System Health Science Center, Albert B. Alkek Institute of Biosciences and Technology, 2121 W, Holcombe Blvd., Suite 603, Houston, TX 77030, USA.
| | | | | | | |
Collapse
|